Market Research Logo

Pulmonary Arterial Hypertension Treatment Market: Lack of Treatment Awareness, Inadequate R&D, & Frequent Drug Rejection Post Clinical Trial to Hamper Growth: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028

Pulmonary Arterial Hypertension Treatment Market: Lack of Treatment Awareness, Inadequate R&D, & Frequent Drug Rejection Post Clinical Trial to Hamper Growth: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028

Market experts at Future Market Insights (FMI) offer a 10-year forecast on the global pulmonary arterial hypertension treatment market with a primary objective to offer actionable insights, updates and, information related to market opportunities in the global pulmonary arterial hypertension treatment market- which in terms of revenue is anticipated to grow at a slow CAGR of 2.5% during the forecast period, 2018–2028. Insights on key trends, drivers, restraints, value forecasts and opportunities for companies operating in the global pulmonary arterial hypertension treatment market are explored and presented in the report.

The global market for Pulmonary arterial hypertension treatment market is expected to witness to grow owing to rising prevalence of pulmonary arterial hypertension disease, increasing adoption of treatment and healthcare spending, huge drug pipeline, and external partnerships in research driving new treatment formulations. These factors are also anticipated to give rise to investment opportunities to key players in the global pulmonary arterial hypertension treatment market.

A key feature of this report- mostly overlooked in other reports is the analysis of key segments in terms of absolute dollar opportunity- which is absolutely critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective for services offered by pulmonary arterial hypertension treatment market. To understand key segments in terms of their growth and performance in the global pulmonary arterial hypertension treatment market, FMI has developed a market attractiveness index to help providers identify existing market opportunities.

Revenue from the pulmonary arterial hypertension treatment market in North America is the most dominating due to increase awareness and improvement in healthcare system. To understand and assess opportunities in this market, the report offers the market forecast on the basis of type into the drug type, distribution channel, and regions. The report provides analysis of the global Pulmonary arterial hypertension treatment market in terms of market value (US$ Mn).

The global pulmonary arterial hypertension treatment market is segmented on the basis of drug type into:

Vasodilators

Phosphodiesterase 5 (PDE 5) inhibitors

Endothelin receptor Antagonists (ERA)

Soluble guanylate cyclase (SGC) stimulator

The report also has a ‘market dynamics’ section, wherein FMI’s analysis key trends, drivers, restraints, opportunities and macro-economic factors influencing the growth of the global pulmonary arterial hypertension treatment market.

The report analyses the market on the basis of the distribution channel and presents an in-depth analysis of:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Next up, the report analyses the market on the basis of regions:

North America

U.S.

Canada

Latin America

Brazil

Mexico

Rest of Latin America

Western Europe

UK

France

Germany

Italy

Spain

BENELUX countries

Nordic Countries

Rest of Western Europe

Eastern Europe

Russia

Poland

Rest of Eastern Europe

Asia Pacific

India

Australia & New Zealand

Rest of APECJ

China

Japan

Middle East & Africa (MEA)

GCC Countries

South Africa

Rest of MEA

In addition, FMI has also considered Year-on-Year (Y-o-Y) growth to understand the predictability of the market and identify growth opportunities for companies operating in the global pulmonary arterial hypertension treatment market.

In the final section of the report, a ‘competitive landscape’ has been included to provide a dashboard view of key companies operating in the global pulmonary arterial hypertension treatment market. The companies analysed are GlaxoSmithKline plc, Eli Lilly and Company, Pfizer Inc., Actelion Inc., (Johnson & Johnson Services, Inc.), United Therapeutic Corporation, SteadyMed Ltd., Gilead Sciences, Inc., Teva Pharmaceuticals Inc., and Bayer AG to name a few. This section is primarily designed to provide a detailed comparative assessment of key providers specific to a market segment in the pulmonary arterial hypertension treatment market and the potential players. This section also includes long- and short-term market strategies and SWOT analysis of the main players operational in the global pulmonary arterial hypertension treatment market.


1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. Hidden Facts
1.4. FMI Analysis and Recommendations
1.5. Wheel of Fortune
2. Market Introduction
2.1. Evolution
2.2. Market Definition
2.3. Market Taxonomy
3. Pulmonary Arterial Hypertension Treatment Market Analysis
3.1. Overview of Pulmonary Arterial Hypertension Treatments
3.2. Macro-Economic Factors
4. Market Background
4.1. Value Chain
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity Analysis
4.3. Regulatory Scenario
4.4. Pipeline Assessment
4.5. Reimbursement Scenario
5. Macroeconomic Assumptions
6. Global Economic Outlook
6.1. Gross Domestic Product by Region & Country, 2016 – 2021
6.2. Disease epidemiology Analysis
7. North America Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028
7.1. Introduction
7.2. Regional Market Trends
7.3. Historical Market Size (US$ Mn) Analysis By Country, 2013–2017
7.3.1. U.S.
7.3.2. Canada
7.4. Market Size (US$ Mn) Forecast By Country, 2018–2028
7.5. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017
7.5.1. Vasodilators
7.5.2. Endothelin receptor antagonists
7.5.3. PDE-5
7.5.4. Soluble guanylate cyclase (SGC) stimulator
7.6. Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028
7.7. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
7.7.1. Hospitals
7.7.2. Retail Pharmacies
7.7.3. Online Pharmacies
7.8. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2028
7.9. Market Attractiveness Analysis
7.9.1. By Country
7.9.2. By Drug Class
7.9.3. By Distribution Channel
7.10.Key Market Participants – Intensity Mapping
7.11.Drivers and Restraints – Impact Analysis
8. Latin America Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028
8.1. Introduction
8.2. Regional Market Trends
8.3. Historical Market Size (US$ Mn) Trends Analysis By Country, 2013–2017
8.3.1. Argentina
8.3.2. Brazil
8.3.3. Mexico
8.3.4. Rest of Latin America
8.4. Market Size (US$ Mn) Forecast By Country, 2018–2028
8.5. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017
8.5.1. Vasodilators
8.5.2. Endothelin receptor antagonists
8.5.3. PDE-5
8.5.4. Soluble guanylate cyclase (SGC) stimulator
8.6. Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028
8.7. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
8.7.1. Hospitals
8.7.2. Retail Pharmacies
8.7.3. Online Pharmacies
8.8. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2028
8.9. Market Attractiveness Analysis
8.9.1. By Country
8.9.2. By Drug Class
8.9.3. By Distribution Channel
8.10.Key Market Participants – Intensity Mapping
8.11.Drivers and Restraints – Impact Analysis
9. Western Europe Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028
9.1. Introduction
9.2. Regional Market Trends
9.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
9.3.1. Germany
9.3.2. U.K.
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Nordic Countries
9.3.7. BENELUX
9.3.8. Rest of Western Europe
9.4. Market Size (US$ Mn) Forecast By Country, 2018–2028
9.5. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017
9.5.1. Vasodilators
9.5.2. Endothelin receptor antagonists
9.5.3. PDE-5
9.5.4. Soluble Guanylate Cyclase (SGC) stimulator
9.6. Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028
9.7. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
9.7.1. Hospitals
9.7.2. Retail Pharmacies
9.7.3. Online Pharmacies
9.8. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2028
9.9. Market Attractiveness Analysis
9.9.1. By Country
9.9.2. By Drug Class
9.9.3. By Distribution Channel
9.10.Key Market Participants – Intensity Mapping
9.11.Drivers and Restraints – Impact Analysis
10. Eastern Europe Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028
10.1.Introduction
10.2.Regional Market Trends
10.3.Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
10.3.1. Russia
10.3.2. Poland
10.3.3. Rest of Eastern Europe
10.4.Market Size (US$ Mn) Forecast By Country, 2018–2028
10.5.Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017
10.5.1. Vasodilators
10.5.2. Endothelin receptor antagonists
10.5.3. PDE-5
10.5.4. Soluble guanylate cyclase (SGC) stimulator
10.6.Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028
10.7.Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
10.7.1. Hospitals
10.7.2. Retail Pharmacies
10.7.3. Online Pharmacies
10.8.Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2028
10.9.Market Attractiveness Analysis
10.9.1. By Country
10.9.2. By Drug Class
10.9.3. By Distribution Channel
10.10.Key Market Participants – Intensity Mapping
10.11.Drivers and Restraints – Impact Analysis
11. Asia Pacific Excluding China & Japan Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028
11.1.Introduction
11.2.Regional Market Trends
11.3.Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
11.3.1. India
11.3.2. Australia and New Zealand
11.3.3. ASEAN Countries
11.3.4. Rest of Asia Pacific
11.4.Market Size (US$ Mn) Forecast By Country, 2018–2028
11.5.Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017
11.5.1. Vasodilators
11.5.2. Endothelin receptor antagonists
11.5.3. PDE-5
11.5.4. Soluble guanylate cyclase (SGC) stimulator
11.6.Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028
11.7.Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
11.7.1. Hospitals
11.7.2. Retail Pharmacies
11.7.3. Online Pharmacies
11.8.Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2028
11.9.Market Attractiveness Analysis
11.9.1. By Country
11.9.2. By Drug Class
11.9.3. By Distribution Channel
11.10.Key Market Participants – Intensity Mapping
11.11.Drivers and Restraints – Impact Analysis
12. China Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028
12.1.Introduction
12.2.Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017
12.2.1. Vasodilators
12.2.2. Endothelin receptor antagonists
12.2.3. PDE-5
12.2.4. Soluble guanylate cyclase (SGC) stimulator
12.3.Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028
12.4.Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
12.4.1. Hospitals
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5.Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2028
12.6.Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Distribution Channel
12.7.Key Market Participants – Intensity Mapping
12.8.Drivers and Restraints – Impact Analysis
13. Japan Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028
13.1.Introduction
13.2.Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017
13.2.1. Vasodilators
13.2.2. Endothelin receptor antagonists
13.2.3. PDE-5
13.2.4. Soluble guanylate cyclase (SGC) stimulator
13.3.Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028
13.4.Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
13.4.1. Hospitals
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5.Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2028
13.6.Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Distribution Channel
13.7.Key Market Participants – Intensity Mapping
13.8.Drivers and Restraints – Impact Analysis
14. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028
14.1.Introduction
14.2.Regional Market Trends
14.3.Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of MEA
14.4.Market Size (US$ Mn) Forecast By Country, 2018–2028
14.5.Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017
14.5.1. Vasodilators
14.5.2. Endothelin receptor antagonists
14.5.3. PDE-5
14.5.4. Soluble guanylate cyclase (SGC) stimulator
14.6.Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028
14.7.Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
14.7.1. Hospitals
14.7.2. Retail Pharmacies
14.7.3. Online Pharmacies
14.8.Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2028
14.9.Market Attractiveness Analysis
14.9.1. By Country
14.9.2. By Drug Class
14.9.3. By Distribution Channel
14.10.Key Market Participants – Intensity Mapping
14.11.Drivers and Restraints – Impact Analysis
15. Forecast Factors: Relevance and Impact
16. Forecast Assumptions
17. Competition Landscape
17.1.Market Structure
17.2.Competition Intensity Mapping By Market Taxonomy
17.3.Competition Dashboard
17.4. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
17.4.1. United Therapeutics Ltd.
17.4.1.1. Overview
17.4.1.2. Key Financials
17.4.1.3. Product and Application Portfolio
17.4.1.4. Recent Developments
17.4.1.5. Strategy
17.4.1.6. SWOT Analysis
17.4.2. Bayer AG
17.4.2.1. Overview
17.4.2.2. Key Financials
17.4.2.3. Product and Application Portfolio
17.4.2.4. Recent Developments
17.4.2.5. Strategy
17.4.2.6. SWOT Analysis
17.4.3. Actelion Ltd.
17.4.3.1. Overview
17.4.3.2. Key Financials
17.4.3.3. Product and Application Portfolio
17.4.3.4. Recent Developments
17.4.3.5. Strategy
17.4.3.6. SWOT Analysis
17.4.4. Pfizer, Inc
17.4.4.1. Overview
17.4.4.2. Key Financials
17.4.4.3. Product and Application Portfolio
17.4.4.4. Recent Developments
17.4.4.5. Strategy
17.4.4.6. SWOT Analysis
17.4.5. Gilead Sciences, Inc.
17.4.5.1. Overview
17.4.5.2. Key Financials
17.4.5.3. Product and Application Portfolio
17.4.5.4. Recent Developments
17.4.5.5. Strategy
17.4.5.6. SWOT Analysis
17.4.6. GlaxoSmithKline plc
17.4.6.1. Overview
17.4.6.2. Key Financials
17.4.6.3. Product and Application Portfolio
17.4.6.4. Recent Developments
17.4.6.5. Strategy
17.4.6.6. SWOT Analysis
17.4.7. Teva Pharmaceuticals Inc.
17.4.7.1. Overview
17.4.7.2. Key Financials
17.4.7.3. Product and Application Portfolio
17.4.7.4. Recent Developments
17.4.7.5. Strategy
17.4.7.6. SWOT Analysis
17.4.8. Eli Lilly and Company
17.4.8.1. Overview
17.4.8.2. Key Financials
17.4.8.3. Product and Application Portfolio
17.4.8.4. Recent Developments
17.4.8.5. Strategy
17.4.8.6. SWOT Analysis
17.4.9. Steady Med Ltd.
17.4.9.1. Overview
17.4.9.2. Key Financials
17.4.9.3. Product and Application Portfolio
17.4.9.4. Recent Developments
17.4.9.5. Strategy
17.4.9.6. SWOT Analysis
17.4.10. Johnson & Johnson Services, Inc
17.4.10.1. Overview
17.4.10.2. Key Financials
17.4.10.3. Product and Application Portfolio
17.4.10.4. Recent Developments
17.4.10.5. Strategy
17.4.10.6. SWOT Analysis
18. Global Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Region
18.1.Introduction / Key Findings
18.2.Historical Market Size (US$ Mn) By Region
18.2.1. North America
18.2.2. Western Europe
18.2.3. Eastern Europe
18.2.4. Latin America
18.2.5. Asia Pacific Excluding China & Japan
18.2.6. China
18.2.7. Japan
18.2.8. Middle East and Africa
18.3.Market Size (US$ Mn) Forecast By Region
18.3.1. North America
18.3.2. Western Europe
18.3.3. Eastern Europe
18.3.4. Latin America
18.3.5. Asia Pacific Excluding China & Japan
18.3.6. China
18.3.7. Japan
18.3.8. Middle East and Africa
18.4.Market Attractiveness Analysis By Region
19. Global Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Drug Class
19.1.Introduction
19.2.Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017
19.2.1. Vasodilators
19.2.2. Endothelin receptor antagonists
19.2.3. PDE-5
19.2.4. Soluble guanylate cyclase (SGC) stimulator
19.3.Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028
19.4.Key Trends / Developments
19.5.Market Attractiveness Analysis By Drug Class Type
20. Global Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channels
20.1.Introduction
20.2.Historical Market Size (US$ Mn) Analysis By Distribution Channels , 2012-2016
20.2.1. Hospitals
20.2.2. Retail Pharmacies
20.2.3. Online Pharmacies
20.3.Market Size (US$ Mn) and Forecast By Distribution Channels , 2017-2027
20.3.1. Hospitals
20.3.2. Retail Pharmacies
20.3.3. Online Pharmacies
20.4.Key Trends / Developments
20.5.Market Attractive Analysis By Distribution Channels
21. Global Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028
21.1.Global Volume Analysis
21.2.Market Size and Y-o-Y Growth
21.3.Absolute $ Opportunity
22. Assumptions and Acronyms Used
23. Research Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report